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Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important
role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To
date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT)
radiotracers available for targeting diﬀerent steps in the process of dopaminergic neurotransmission, which permits us to quantify
dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson’s disease
(PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing eﬀects
of drug abuse. Abnormalities within the dopamine system in the brain are involved in the pathophysiology of attention deﬁcit
hyperactivity disorder (ADHD). Dopamine receptors play an important role in schizophrenia and the eﬀect of neuroleptics is
throughblockageofdopamineD2 receptors.Thisreviewwillconcentrateontheradiotracersthathavebeendevelopedforimaging
dopaminergic neurons, describe the clinical aspects in the assessment of neuropsychiatric disorders, and suggest future directions
in the diagnosis and management of such disorders.
1.Introduction
Neuropsychiatricdisorderscauseseverehumansuﬀeringand
are becoming a major socioeconomic burden to modern
society. The rapid development of noninvasive tools for
imaging human brains will improve our understanding of
complex brain functions and provide more insight into the
pathophysiology of neuropsychiatric disorders. Neuroimag-
ing techniques currently utilized in neuropsychiatric disor-
ders include a variety of modalities, such as ultrasound, X-
rays, computed tomography (CT), functional magnetic res-
onance imaging (fMRI), and nuclear medicine imaging [1].
The interactions between transporters/receptors and
neurotransmitters play a key role in the diagnosis and
treatment of neuropsychiatric disorders. In contrast with
conventional diagnostic imaging procedures, which simply
provide anatomical or structural pictures of organs and
tissues, nuclear medicine imaging is the only tool to visualize
the distribution, density, and activity of neurotransmitters,
receptors, or transporters in the brain. Nuclear medicine
imaging involves the administration of radioactively labeled
tracers, which decay over time by emitting gamma rays
that can be detected by a positron emission tomography
(PET) or single photon emission computed tomography
(SPECT) scanner [2, 3]. PET uses coincidence detection in
lieu of absorptive collimation to determine the positron-
electron annihilation, which produces two 511keV photons
in opposite direction. This partially explains the greater
spatial resolution and sensitivity of PET. Radioisotopes used
in PET imaging typically have short physical half-life and
consequently many of them have to be produced with
an on-site cyclotron. Radioisotopes used for labeling PET
radiopharmaceuticals include 11C, 13N, 15O, 18F, 64Cu, 62Cu,
124I, 76Br, 82Rb, and 68Ga, with 18F being the most clinically
utilized. SPECT radiotracers typically have longer physical
half-life than most PET tracers; thus a central radiopharma-
ceutical laboratory can prepare radiotracers for delivery to
SPECT facilities within a radius of several hundred miles.
There are a range of radioisotopes (such as 99mTc, 201Tl,
67Ga, 123I, and 111In) that can be used for labeling SPECT2 Journal of Biomedicine and Biotechnology
radiopharmaceuticals,dependingonthespeciﬁcapplication.
99mTc is the most used radionuclide for nuclear medicine
becauseitisreadilyavailable,relativelyinexpensive,andgives
lower radiation exposure [2–4].
A major advantage of nuclear medicine imaging is the
extraordinarily high sensitivity: a typical PET scanner can
detect between 10−11mol/L to 10−12mol/L concentrations,
whereas MRI has a sensitivity of around 10−3mol/L to
10−5mol/L [4]. Because many molecules relevant to neu-
ropsychiatric disorders are present at concentrations below
10−8M, nuclear medicine imaging is currently the only
available in vivo method capable of quantifying subtle
cerebral pathophysiological changes that might occur before
neurostructural abnormalities take place [5].
Radiotracers must fulﬁll several criteria to be successful
for PET or SPECT imaging: including readily labeled with
appropriate radionuclide and the labeled radiotracer being
stable in vivo and nontoxic; suﬃcient aﬃnity and high
selectivity for the speciﬁc receptor combined with low
nonspeciﬁc binding to brain tissue not containing the
receptor of interest; rapid permeation through the blood-
brain barrier permitting high access of tracers to receptors,
aswellasallowinghighinitialbrainuptakeandfastclearance
of the activity from the brain. A large number of radiotracers
have been developed for brain imaging, but most of them
were utilized only in vitro or in experimental animals and
only few have the potentiality in clinical practice. Selective
radiotracers are available for the study of dopaminergic,
acetylcholinergic, serotonergic, and norepinephrine systems,
as well as β-amyloid plaques with promising results [5, 6].
Dopamine is the most intensely studied monoaminergic
neurotransmitter. Dopaminergic neurotransmission plays
an important role in regulating several aspects of basic
brain function, including motor, behavior, motivation, and
working memory, and is involved in the pathogenesis of
several psychiatric and neurological disorders. Degeneration
of the nigrostriatal dopamine system causes Parkinson’s
disease (PD) and related Parkinsonism. Postsynaptic recep-
tors may be involved in neurodegenerative disorders; they
are functionally changed in Parkinsonism. Dopamine is
thought to be involved in drug abuse. Most drugs of abuse,
with the exception of benzodiazepines, have a direct eﬀect
on increasing the dopamine reward cycle in the brain.
Abnormalities within the dopamine system in the brain
play a major role in the pathophysiology of attention deﬁcit
hyperactivity disorder (ADHD). Dopamine receptors also
play an important role in schizophrenia and the eﬀect of
neuroleptics is through blockage of dopamine D2 recep-
tors [6]. Neuroimaging techniques permit us to quantify
dopaminergic activity in the living human brain, which has
become increasingly part of the assessment and diagnosis
of neuropsychiatric disorders. To date, there are numerous
PET and SPECT radiotracers available for targeting diﬀerent
stepsintheprocessofdopaminergicneurotransmission.This
paper will concentrate on the radiotracers that have been
developed for imaging dopaminergic neurons, describe their
unique strengths and limitations in the assessment of neu-
ropsychiatric disorders, and suggest future directions in the
diagnosis and management of neuropsychiatric disorders.
2. Radiotracersfor Imaging
DopaminergicNeurons
Diagnosis of neurological and psychiatric disorders associ-
ated with disturbances of dopaminergic functioning can be
challenging, especially in the early stages. The evolution of
neuroimaging technique over the past decade has yielded
unprecedented information about dopaminergic neurons.
PET and SPECT techniques have been successfully employed
to visualize the activity of dopamine synthesis, reuptake
sites, and receptors (Table 1). The Chemical structure of
various radiotracers for the assessment of dopamine system
is illustrated on Figure 1. DOPA decarboxylase activity
and dopamine turnover can both be measured with 18F-
DOPA or 18F-FMT PET [7]. 18F-DOPA PET was the ﬁrst
neuroimaging technique validated for the assessment of
presynapticdopaminergicintegrity.Theuptakeof 18F-DOPA
reﬂects both the density of the axonal terminal plexus and
the activity of the striatal aromatic amino acid decarboxylase
(AADC), the enzyme responsible for the conversion of 18F-
DOPA to 18F-dopamine. However, AADC is present in the
terminals of all monoaminergic neurons, measurements of
18F-DOPA uptake into extrastriatal areas provides an index
of the density of the serotonergic, norepinephrinergic, and
dopaminergic terminals [8–10].
Dopamine transporter (DAT) is a protein complex
located in presynaptic dopaminergic nerve terminals, which
serves as the primary means for removing dopamine from
the synaptic cleft. The availability of presynaptic DAT can
be assessed with various radiotracers, which are typically
tropane based [7, 11]. Several PET tracers (11C-CFT, 18F-
CFT, 18F-FP-CIT, and 11C-PE2I) and SPECT tracers such as
123I-β-CIT (Dopascan), 123I-FP-CIT (ioﬂupane, DaTSCAN),
123I-altropane, 123I-IPT, 123I-PE2I, and 99mTc-TRODAT-1
are now available to measure DAT availability [8, 11–
17]. 123I-β-CIT was the ﬁrst widely applied SPECT tracer
in imaging DAT, however, the lack of speciﬁcity is a
disadvantage. This radiotracer binds not only to DAT but
also to norepinephrine transporter (NET) and serotonin
transporter (SERT). Another disadvantage of 123I-β-CIT is
considered not convenient for routine out-patient evalu-
ations since adequate imaging should be performed 20–
30h following the injection [11]. The faster kinetics of 123I-
FP-CIT is a clear advantage for clinical use, which allows
adequate acquisition as early as 3h following injection [18].
Conversely, 123I-altropane SPECT images have been less
extensively investigated and are more diﬃcult to quantify
owingtorapidwashoutfromthebrain[19].Thetechnetium
based 99mTc-TRODAT-1hastheadvantageofbeingrelatively
inexpensive and available in kit form. The easy preparation
of 99mTc-TRODAT-1 from lyophilized kits could be an
ideal agent for daily clinical application [16]. However, its
speciﬁc signal is lower than the 123I-based SPECT tracers.
To date, only DaTSCAN (123I-FP-CIT) and 99mTc-TRODAT-
1 are commercially available in the market and licensed for
detecting loss of functional dopaminergic neuron terminals
in the striatum.
In the brain, dopamine activates the ﬁve known types
of dopamine receptors—D1,D 2,D 3,D 4,a n dD 5. DopamineJournal of Biomedicine and Biotechnology 3
Table 1: Radiotracers available for targeting diﬀerent steps in the process of dopaminergic neurotransmission and clinical applications.
Targeting Tracer Chemical name Clinical studies (references)
Dopamine
synthesis and turn
over
18F-DOPA L-3,4-dihydroxy-6-[18F]-ﬂuorophenylalanine PD [11, 20–23], gene therapy for PD [24–26],
ADHD [27], schizophrenia [28, 29]
18F-FMT O-[18F]-ﬂuoromethyl-D-tyrosine Gene therapy for PD [30, 31]
Dopamine
transporter
11C-CFT [11C]-2β-carbomethoxy-3β-ltropane Heroin abuse [32]
11C-altropane 2β-carbomethoxy-3β-(4-ﬂuorophenyl)-N-
((E)-3-iodo-prop-2-enyl)tropane ADHD [33]
123I-β-CIT
(Dopascan)
[123I]-(1R)-2-β-carbomethoxy-3-β-(4-
iodophenyl)-tropane
PD [11, 20], PM [34], PD & ET [35], cocaine
abuse [36, 37], ADHD [38]
123I-FP-CIT
(DaTSCAN)
[123I] N-ω-ﬂuoropropyl-2β-carbomethoxy-3β-
(4-iodophenyl)
nortropane
PM [39–41], PM & ET [42], PD & DLB [43], AD,
PD & DLB [44], ADHD [45–47], schizophrenia
[48]
99mTc-TRODAT-1
[99mTc]technetium [2-[[2-[[[3-(4-
chlorophenyl)-8-methyl-8-azabicyclo
[3.2.1]oct-2-yl]-methyl](2-
mercaptoethyl)amino]-ethyl]amino]ethane-
thiolato(3-)-N2,N2 ,S2,S2 ]oxo-[1R-(exo-
exo)]
PD [23, 49–51], MSA [52], PM & VP [53], DRD
[54], PSP [55], genetic study of PD [51, 56],
genetic study of MJD [57], cocaine abuse [58],
opiate abuse [59], nicotine dependence [60, 61],
ADHD [62–68]
123I-altropane
[123I]-2β-carbomethoxy-3β-(4-ﬂuorophenyl)-
N-(1-iodoprop-1-en-3-yl)
ortropane
PD [21], ADHD [69]
123I-IPT
[123I]-N-(3-iodopropen-2-yl)-2-
carbomethoxy-3beta-(4-chlorophenyl)
tropane
ADHD [70]
Dopamine D1
receptor
11C-NNC 112
(+)-5-(7-Benzofuranyl)-8-chloro-7-hydroxy-
3-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine
Schizophrenia [71]
11C-SCH 23390 (R)-(+)-8-Chloro-2,3,4,5-tetrahydro-3-
[11C]methyl-5-phenyl-1H-3-benzazepin-7-ol Schizophrenia [72, 73]
Dopamine D2
receptor
11C-Raclopride
3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-
yl]methyl}-2-hydroxy-6-
[11C]methoxybenzamide
Drug abuse [74–79] cocaine abuse [80, 81],
methamphetamine abuse [82], opiate abuse [83],
alcohol dependence [84], ADHD [85, 86],
antipsychotics [48, 87–89]
123I-IBZM (S)-(-)-3-[123I]iodo-2-hydroxy-6-methoxy-N-
[(1-ethyl-2-pyrrolidinyl)methyl]benzamide
PM [40, 41], schizophrenia [90], antipsychotics
[89, 91, 92]
vesicular
monoamine
transporter type-2
11C-DTBZ (±)-α-[11C]dihydrotetrabenazine PD [7, 11, 20]
18F-FP-DTBZ
(AV-133) 9-[18F]ﬂuoropropyl-(+)-dihydrotetrabenazine PD [93], DLB & AD [94]
Abbreviations: Parkinson’s disease (PD), Parkinsonism (PM), multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), essential tremor (ET),
vascular Parkinsonism (VP), Machado-Joseph disease (MJD), DOPA-responsive dystonia (DRD), dementia with Lewy bodies disease (DLB), Alzheimer’s
disease (AD), and attention deﬁcit hyperactivity disorder (ADHD).
receptors belong to the G-protein-coupled superfamily. The
dopamine D1 and D5 receptor subtypes are known as D1-like
receptors and couple to inhibitory G-proteins, whereas the
dopamineD2,D 3,D 4 receptorsubtypesareknownasD2-like
familyandcoupletostimulatoryG-proteins.Onlydopamine
D1 and D2 r e c e p t o r sh a v eb e e ni m a g e di nh u m a n s .F o r
dopamineD1 subtype,themostcommonlyusedradiotracers
are 11C-SCH23390 and 11C-NNC112 [7]. As assessment of
D1-like receptors has not gained clinical signiﬁcance; there-
foremanyinvestigationshavefocusedontheD2-likereceptor
system in the past. Dopamine D2 receptors are assessed
most commonly with the use of benzamide radiotracers.
11C-raclopride, 18F-spiperone, and 18F-methyl-benperidol
have been developed for PET imaging; alternatively, 123I-
IBZM (123I-iodobenzamide), 123I-epidrpride, and 123I-IBF
have been developed for SPECT imaging. 11C-raclopride is
currently the gold standard PET tracer for dopamine D2
receptors. In contrast to 11C-raclopride, with a physical half-
life of approximately 20min, 123I-IBZM allows shipment
over considerable distances since the radiotracer has a
longer physical half-life of 13.2h [95, 96]. 123I-epidrpride,
displaying very high aﬃnity to D2/D3 receptors, has been
exploited for quantiﬁcation and visualization of low density
extrastriatal D2/D3 receptors [97].
The vesicular monoamine transporter type 2 (VMAT2)
is expressed by all monoaminergic neurons and serves
to pump monoamines from cytosol into synaptic vesicles
thereby protecting the neurotransmitters from catabolism
by cytosolic enzymes and packaging them for subsequent
exocytotic release [98]. In striatum, more than 95% of4 Journal of Biomedicine and Biotechnology
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Figure 1: Chemical structure of various radiotracers for the assessment of dopamine synthesis, reuptake sites, and receptors.
VMAT2 is associated with dopaminergic terminals and
VAMT2 concentration linearly reﬂects to the concentration
of dopamine in the striatum [20, 99]. The most widely used
radiotracer is [11C]dihydrotetrabenazine (DTBZ), which
binds speciﬁcally and reversibly to VMAT2 and is amenable
to quantiﬁcation of striatal, diencephalic, and brain stem
neurons and terminals with PET [98]. The 18F-labeled
VAMT2 tracer, 18F-FP-DTBZ (AV-133), has been developed
with the advantage of having a half-life of nearly 2h, which
allowsshipmentoftracersoverconsiderabledistancestoPET
centers without an on-site cyclotron [93, 100].
3. Parkinson’s Disease andOther
Movement Disorders
Parkinson’s disease, the second most common neurode-
generative disorder, is characterized by severe loss of
dopamine neurons, resulting in a deﬁciency of dopamine
[101, 102]. Clinical diagnosis of Parkinson’s disease relies on
the presence of characteristic motor symptoms, including
bradykinesia, rigidity and resting tremors, but the rate of
misdiagnosis of Parkinson’s disease using this method was as
high as 24% according to previous studies [103–105]. Good
response to dopaminergic drugs, particularly levodopa, is
often used to support the clinical diagnosis of Parkinson’s
disease. However, some patients with pathologically con-
ﬁrmed Parkinson’s disease have a poor response to levodopa;
conversely, some patients with early multiple-system atro-
phy (MSA) or progressive supranuclear palsy (PSP) have
beneﬁcial responses to drug treatment [106]. Since the
introduction of in vivo molecular imaging techniques, the
diagnosis of Parkinson’s disease became more reliable by
assessing dopaminergic and even nondopaminergic systems
[107].
ImagingofstriataldenervationinParkinson’sdiseasewas
ﬁrst reported with 18F-DOPA PET and has been extended in
imaging studies of DAT and VMAT2 [11, 13, 14, 21–23, 34,
39, 49, 94, 98, 108]. All these markers demonstrate reduced
uptake in the striatum, the location of the presynaptic
nigral dopamine terminal projections. More speciﬁcally,
these imaging studies in Parkinson’s disease patients have
shown the nigral neuron loss is asymmetric, where the
putamenal reductions are more profound than those in
caudate [10]. Studies with 18F-DOPA and DAT tracers
indicated a reduction in radiotracer uptake of approximately
50–70% in the putamen in Parkinson’s disease subjects
[21, 34, 39, 49]. In general, all these DAT markers show
similar ﬁndings in Parkinson’s disease to those seen with 18F-
D O P AP E Ta n da r ea b l et od i ﬀerentiate early Parkinson’s
disease from normal subjects with a sensitivity of around
90% [6, 50]. A multicenter phase III trial conducted at
Institute of Nuclear Energy Research (INER) in Taiwan
indicated that patients with Parkinson’s disease were easily
distinguished from healthy volunteers with 99mTc-TRODAT-
1 SPECT, which had a sensitivity of 97.2% and a speciﬁcity
of 92.6% (unpublished data).
18F-DOPA PET is considered as a standard procedure
for evaluating dopaminergic metabolism. However, use of
18F-DOPA PET may sometimes overestimate the nigral cell
reserve in Parkinson’s disease, since it may show a better than
actualuptakeduetocompensatoryincreasedactivityofdopa
decarboxylase that occurs with dopamine cell terminal loss
[11]. On the contrary, the striatal uptake of DAT radiotracers
in early Parkinson’s disease may overestimate the reduction
in terminal density due to the relative downregulation of
DAT in the remaining neurons as a response to nigral neuron
loss, a compensatory mechanism that acts to maintain
synaptic dopamine levels [23]. Additionally, DAT activity
falls with age in healthy subjects, but striatal 18F-DOPA
uptake does not appear to be age dependent [8, 9, 22].
The signs and symptoms present in early Parkinson’s dis-
ease can resemble those of many other movement disorders,
particularly other forms of parkinsonism such as progressive
supranuclear palsy, progressive supranuclear palsy, drug-
induced Parkinsonism (DIP), vascular Parkinsonism (VP),
dementia with Lewy bodies (DLB), and essential tremor
(ET) [10, 40]. It is important to discriminate between
idiopathic Parkinson’s disease (IPD) and other neurodegen-
erative Parkinsonian syndromes because there are marked
diﬀerences in the prognoses and therapies.
Neuroimaging studies indicate that the pattern of do-
paminergic neurons loss in Parkinsonian syndromes is less
region-speciﬁc than in idiopathic Parkinson’s disease, the
putamen and caudate are more equally eﬀected. Moreover,
left and right striatal radiotracer uptake in these disorders is
also more symmetric than in idiopathic Parkinson’s disease
[10]. Lu et al. found DAT imaging with 99mTc-TRODAT-
1 probably could provide important information to dif-
ferentiate progressive supranuclear palsy from Parkinson’s6 Journal of Biomedicine and Biotechnology
99mTc-TRODAT-1
123I-IBZM
Healthy volunteer Parkinson’s disease MSA PSP
Figure 2: Dopamine transporter (DAT) imaging with 99mTc-TRODAT-1 and dopamine D2 receptor imaging with123I-IBZM of healthy
volunteerandpatientswithParkinson’sdisease(PD),multiple-systematrophy(MSA),andprogressivesupranuclearpalsy(PSP).Thestriatal
DAT uptakes were signiﬁcantly decreased in patients with PD, MSA, and PSP, whereas the dopamine D2 receptor uptakes were mildly
decreased in patients with PD, MSA, and PSP.
disease.Thestriatalbindingwasmoresymmetricallyreduced
in patients with progressive supranuclear palsy, in contrast
to the greater asymmetric reduction in the Parkinson’s
disease groups [52]. Essential tremor is a condition most
commonly misdiagnosed with Parkinson’s disease; up to
25% of cases are initially diagnosed as having Parkin-
son’s disease. DAT imaging using 123I-β-CIT and 123I-FP-
CIT SPECT has been successfully proven in diﬀerentiating
essential tremor from Parkinson’s disease; subjects with
essential tremor have normal levels of striatal uptake. Such
studies have found the sensitivity and speciﬁcity for clinical
diagnosis of distinguishing Parkinson’s disease fromessential
tremor to be 95% and 93%, respectively [35, 42]. Vascular
Parkinsonism is a disorder caused by cerebrovascular disease
and accounts for 4.4–12% of all cases of Parkinsonism [109].
Dopaminergic imaging studies may help with the diagnosis
of vascular Parkinsonism, although studies have provided
conﬂicting results. Two studies (using 123I-β-CIT or 99mTc-
TRODAT-1 SPECT) found near normal DAT binding in
patients with vascular Parkinsonism, diﬀerentiating them
from patients with Parkinson’s disease, whereas other studies
have found reduced DAT binding in some patients with
vascular Parkinsonism [19, 34, 53]. Dementia with Lewy
bodies, characterized by severe nigrostriatal dopaminergic
neuron degeneration, is the second most common form
of degenerative dementia (after Alzheimer’s disease, AD).
Accurate diagnosis in Alzheimer’s disease and dementia
with Lewy bodies is particularly important in the early
stage of the disease for the treatment and management
of the patient. 18F-DOPA, DAT, and VMAT2 markers can
diﬀerentiate dementia with Lewy bodies, who display lower
striatalbindingintheputamen,caudate,andmidbrain,from
those with Alzheimer’s disease, who have normal striatal
binding similar to those observed in healthy controls. Mean
sensitivity of 123I-FP-CIT scans for a clinical diagnosis of
probable dementia with Lewy bodies was 77.7%, while the
mean speciﬁcity for excluding non-Lewy body dementia was
90.4%, giving overall diagnostic accuracy of 85.7% [19, 43,
44, 94]. In addition, a DAT study with 99mTc-TRODAT-
1 scan in DOPA-responsive dystonia (DRD) patients, a
hereditary progressive disorder with sustained response to
low-dosage levodopa but entirely diﬀerent prognosis from
Parkinson’s disease, showed signiﬁcant higher DAT uptake
in patients with DOPA -responsive dystonia than those in
patients with young onset Parkinson disease (P<0.001),
suggesting a normal nigrostriatal presynaptic dopaminergic
terminal in DOPA -responsive dystonia [54].
Higher diagnostic accuracy in the diﬀerential diag-
nosis of Parkinsonism may be achieved by combining
pre- and postsynaptic quantitative information about the
dopaminergic system. Previous imaging studies with the
most commonly used dopamine D2 receptor tracers, 11C-
raclopride and 123I-IBZM, have shown that the uptake of
DAT are downregulated in patients with early idiopathic
Parkinson’s disease, but D2 receptors are comparable to
normal subjects in medicated Parkinson’s disease patients
and may even be mildly increased in unmedicated patients.
With the progression of Parkinson’s disease, striatal D2
receptor activity returns to normal or may fall below normal
levels [98]. In contrast to Parkinson’s disease, patients with
atypical Parkinsonism like progressive supranuclear palsy
or progressive supranuclear palsy typically show reductions
in both DAT and D2 binding [7, 40, 41]. Figure 2 illus-
trates the DAT scans with 99mTc-TRODAT-1 and the D2
receptor scans with 123I-IBZM of healthy volunteer and
patients with Parkinson’s disease, multiple system atrophy,
and progressive supranuclear palsy. However, the small
diﬀerences in D2 binding failed to discriminate between
idiopathic Parkinson’s disease, nonidiopathic Parkinson’s
disease, and healthy control groups, according to a report ofJournal of Biomedicine and Biotechnology 7
a multicenter phase III trial conducted by INER (unpub-
lished data). Nevertheless, the dopamine D2 receptor
imaging is successfully demonstrated in diﬀerentiation of
the subtypes of progressive supranuclear palsy: Richard-
son’s syndrome (RS) and progressive supranuclear palsy-
parkinsonism (PSP-P). Assessment of pre- and postsynaptic
dopaminergic activities in Richardson’s syndrome, PSP-P, or
idiopathic Parkinson’s disease with 99mTc-TRODAT-1 and
123I-IBZM images showed that the activities of D2 receptor
were reduced in Richardson’s syndrome but not in PSP-
P( P<0.01), which was consistent with the clinical
manifestation of PSP-P group with better prognosis and
levodopa responsiveness than that of RS patients [55].
Imaging the distribution and density of single molecules
inthelivingbrainwillgiveusstraightforwardinformationof
thegeneticlinkagesamongdiﬀerentaspectsofParkinsonism.
Genetic studies have identiﬁed at least 9 genes with mutation
that cause 10% to 15% of Parkinson’s disease cases [103].
SNCA,Parkin,PINK1,DJ-1,LRRK2,andATP13A2havebeen
identiﬁed to be the causative genes for familial and early
onset Parkinson’s disease (EOPD) [51]. A 99mTc-TRODAT-
1 scan revealed that patients with the PINK1 mutation
displayed a rather even, symmetrical reduction of dopamine
uptake, whereas patients with late-onset Parkinson’s disease
(LOPD) displayed a dominant decline in dopamine uptake
in the putamen [56]. The contribution of genetic variants
in ATP13A2 to Parkinson’s disease of Taiwanese patients was
investigatedwith 99mTc-TRODAT-1SPECT,showingthatthe
striatal uptake of patients carrying the variants of G1014S
and A746T were similar to that of idiopathic Parkinson’s
disease [51]. In addition, 99mTc-TRODAT-1 SPECT was
exploited to examine the DAT activity in Machado-Joseph
disease (MJD) patients and gene carriers, showing that the
DATconcentrationwassigniﬁcantlyreducedinpatientswith
Machado-Joseph disease and in asymptomatic gene carriers
compared to those of healthy volunteers (P<0.001) [57].
Molecular imaging is also a major tool for the evaluation
ofnewexperimentaltherapeuticstrategiesinParkinson’sdis-
ease. Cell transplantation to replace lost neurons is a recent
approach to the treatment of progressive neurodegenerative
diseases. Transplantation of human embryonic dopamine
neurons into the brains of patients with Parkinson’s disease
has proved beneﬁcial in open clinical trials [7, 24]. Sev-
eral teams of investigators have reported the results from
double-blind placebo-controlled trials of human embryonic
dopaminergic tissue transplantation for the treatment of
Parkinson’s disease. Evaluations with 18F-DOPA scans have
shown that signiﬁcant declines in the motor scores over time
after transplantation (P<0.001), based on the Uniﬁed
Parkinson Disease Rating Scale (UPDRS), were associated
with increases in putamen 18F-DOPA uptake at 4 years
posttransplantation followups (P<0.001). Furthermore,
posttransplantation changes in putamen PET signals and
clinical outcomes were signiﬁcantly intercorrelated (P<
0.02) [24, 25]. Gene therapy may be potentially useful
for ameliorating the motor symptoms of Parkinson’s dis-
ease. Several gene therapy studies in humans investigated
transductions (with various viral vectors) of glial-derived
neurotrophic factor (GDNF), neurturin (NTN), AADC, or
glutamic acid decarboxylase (GAD). Brain imaging with
18F-DODA or 18F-FMT PET has been exploited to evaluate
clinical outcomes adjunct to the UPDRS scores [26, 30, 31,
110–112].
4.DrugAbuse andAddicted Brain
Dopamine is the neurotransmitter that has been classically
associated with the reinforcing eﬀects of drug abuse. This
notion reﬂects the fact that most of the drugs of abuse
increase extracellular dopamine concentration in limbic
regions including nucleus accumbens (NAc). The involve-
ment of dopamine in drug reinforcement is well recognized
but its role in drug addiction is much less clear. Imaging
studies have provided evidences of how the human brain
changes as an individual becomes addicted [74–77].
Cocaine is considered one of the most reinforcing
drug of abuse; therefore, this drug has been extensively
investigated the associated reinforcing eﬀects in humans.
Cocaine is believed to work by blocking the DAT and
thereby increasing the availability of free dopamine within
the brain. The relationship between DAT blockage and the
reinforcement eﬀects of cocaine abuser has been assessed
with 11C-cocaine PET, showing that intravenous cocaine at
doses commonly abused by human (0.3–0.6mg/kg) blocked
between 60 to 77% of DAT sites in these subjects. Moreover,
the magnitude of the self-reported “high” was positively
correlated with the degree of DAT occupancy, and at least
47% of the transporters had to be blocked for subjects to
perceive cocaine’s eﬀects [80]. When compared to normal
controls, cocaine abusers showed signiﬁcant decreases in
dopamine D2 receptor availability that persisted 3-4 months
after detoxiﬁcation. Decreases in dopamine D2 receptor
availability were associated with decreased metabolism in
several regions of the frontal lobes, most markedly in orbito-
frontal cortex and cingulate gyri [81]. PET studies with 11C-
raclopride have consistently shown that subjects with a wide
variety of drug addictions (cocaine, heroin, alcohol, and
methamphetamine) have signiﬁcant reductions in dopamine
D2 receptor availability in the striatum that persist months
after protracted detoxiﬁcation [76, 78, 82–84, 113].
SincedopamineD2 receptorsareinvolvedintheresponse
to reinforcing properties of natural as well as drug stimuli,
it has been postulated that reduced D2 receptor levels in
drug-addicted subjects would make them less sensitive to
natural reinforcers. Volkow et al. compared the function
of the dopamine system of 20 cocaine-dependent subjects
with 23 controls using 11C-raclopride PET by measuring
the relative changes in extracellular dopamine induced by
intravenous methylphenidate. Cocaine-dependent subjects
showed reduced dopamine release in the striatum and
also had a reduced “high” relative to controls, indicating
that methylphenidate-induced striatal dopamine increased
incocaineabusersweresigniﬁcantlybluntedwhencompared
with those of controls [74, 113].
Despite the similarities between cocaine and meth-
ylphenidate in their aﬃnity to the DAT, cocaine is much
more abused than methylphenidate. Using 11C labeled
cocaine and methylphenidate for PET imaging, it has8 Journal of Biomedicine and Biotechnology
been demonstrated that the regional distribution of 11C-
methylphenidate was identical to that of 11C-cocaine and
they competed with each other for the same binding
site. However, these two drugs diﬀered markedly in their
pharmacokinetics. Both drugs entered the brain rapidly
after intravenous administration (in less than 10min) while
the rate of clearance of 11C-methylphenidate from striatum
(90min) was signiﬁcantly slower than that of 11C-cocaine
(20min). Therefore, it is postulated that the initial uptake
of these stimulant drugs into the brain, not their steady-
state presence, is necessary for drug-induced reinforcement
[76, 114].
In addition to diﬀerences in bioavailability, the route of
administration signiﬁcantly aﬀects the eﬀects of stimulant
drugs presumably via its eﬀects on pharmacokinetics. This
is particularly relevant to methylphenidate because it is
abused when taken intravenously but rarely so when taken
orally.Volkowetal.measuredthedopaminechangesinduced
by oral and intravenous administration of methylphenidate
that produce equivalent DAT occupancy (about 70%). Even
though the dopamine increases were comparable for oral
and intravenous (approximately 20% changes in speciﬁc
bindingof 11C-racloprideinstriatum),oralmethylphenidate
did not induce signiﬁcant increases in self-reports of “high.”
Intravenous administration of methylphenidate leads to fast
dopamine changes, whereas oral administration increases
dopamine slowly. The failure to observe the “high” with oral
methylphenidate is likely to reﬂect the slower pharmacoki-
netics [76, 77, 85].
AviewofDATregulationincocaineaddictsmayimprove
our understanding of clinical aspects of cocaine dependence,
including drug-induced carving, dysphoria, and relapse. The
D A Tl e v e l si nt h eb r a i no fc o c a i n e - d e p e n d e n c ew e r em e a -
sured by 99mTc-TRODAT-1 SPECT. It has shown that there
were signiﬁcantly higher DAT levels in cocaine-dependent
subjects compared to controls for the anterior putamen,
posterior putamen, and caudate. DAT levels in these regions
were 10%, 17%, and 8% higher in the cocaine dependent
subjects compared to controls. This study also showed that
99mTc-TRODAT-1 uptake was negatively correlated with the
duration of time since last use of cocaine [58]. Malison et
al. examined the striatal DAT levels in 28 cocaine-abusing
subjects with 123I-β-CIT SPECT and found that striatal
DAT levels were signiﬁcantly increased (approximately 20%)
in acutely abstinent cocaine-abusing subjects (96h or less)
[36]. Another study using 123I-β-CIT SPECT also showed
approximately a 14% increase in DAT availability in acutely
abstinent (3.7 days on average) cocaine subjects compared to
controls [37].
Human imaging studies suggest that preexisting dif-
ferences in dopamine circuits may be one mechanism
underlying the variability in responsiveness to drug abuse.
In particular, baseline measures of striatal dopamine D2
receptorsinnonaddictedsubjectshavebeenshowntopredict
subjective responses to the reinforcing eﬀects of intra-
venous methylphenidate treatment. Individuals describing
the experience as pleasant had substantially lower levels
of dopamine D2 receptors compared with those describing
methylphenidate as unpleasant [74, 79].
Methadone maintenance treatment has been demon-
strated to be eﬀective in reducing or eliminating opioid
drug use. Despite its therapeutic eﬀectiveness, relatively
little is known about neuronal adaptations in the brains of
methadone users. A PET study with 11C-CFT has docu-
mented reduced DAT availability in patients with prolonged
abstinence and with methadone maintenance treatment.
Furthermore, the subjects with methadone maintenance
treatment showed signiﬁcant decreases of DAT uptake
function in the bilateral putamen in comparison to the
prolonged abstinence subjects [32]. Another study examined
the diﬀerences between opioid-dependent users treated with
a very low dose of methadone or undergoing methadone-
free abstinence. The striatal DAT availability was signiﬁ-
cantly reduced in low-dose methadone users (0.78 ± 0.27)
and methadone-free abstinence (0.94 ± 0.28) compared
to controls (1.16 ± 0.26), which has demonstrated that
methadone treatment or abstinence can beneﬁt the recovery
of impaired dopamine neurons. Moreover, lower midbrain
SERT availability also was noted in methadone maintenance
treatment and methadone-free abstinence groups, which
implicated deregulation of serotoninergic neurons in opioid
abuse [59].
The behavioral and neurobiological eﬀects of tobacco
smoking, in which nicotine may play an import role, are
similartothoseofaddictivedrugs.Thepre-andpostsynaptic
activity of dopamine neuron was examined in male smokers
with 99mTc-TRODAT-1/123I-IBZM SPECT. A decrease in
DAT availability was found in the striatum of male smokers
(P<0.05), suggesting cigarette smoking may alter central
dopamine functions, particularly at the presynaptic sites.
Moreover, the total FTND (Fagerstr¨ om Test for Nicotine
Dependence) scores correlated negatively with striatal DAT
availabilityinmalesmokers,butnotwithstriatalD2 bindings
[60].
5. Attention Deﬁcit HyperactivityDisorder
Attention deﬁcit hyperactivity disorder (ADHD) is a com-
mon disorder of childhood characterized by inattention,
excessive motor activity, impulsiveness, and distractibility. It
is associated with serious disability in children, adolescents
and adults. There is converging evidence that abnormalities
within the dopamine system in the brain play a major role in
thepathophysiologyofADHD[33,62,63].Despiteextensive
investigation of the neuropathophysiology of ADHD by a
wide array of methodologies, the mechanism underlying this
disorder is still unknown.
Neuroimaging holds promise forunveiling the neurobio-
logicalcausesofADHDandprovidesinvaluableinformation
for management of the disease. Ernst et al. investigated the
integrity of presynaptic dopaminergic function in children
with ADHD through the use of 18F-DOPA PET and found a
48% increase in DOPA decarboxylase activation in the right
midbraininADHDchildrencomparedwithnormalcontrols
[27].
Methylphenidate is considered as a ﬁrst-line medication
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is very eﬀective for the treatment of ADHD; it is estimated
that 60–70% of ADHD subjects have favorable responses.
Volkow et al. utilized 11C-cocaine and 11C-raclopride PET
to assess the DAT and dopamine D2 receptor occupancy
for a given dose of methylphenidate. It has been proven
that this drug signiﬁcantly blocked DAT (60 ± 11%) and
increased synaptic dopamine levels (16 ± 8%) reduction in
11C-raclopride binding in the striatum [86].
It is widely accepted that the therapeutic eﬀects of
methylphenidate are through the blocking of DAT; therefore,
it seems appropriate to investigate the DAT availability in
patients with ADHD. The ﬁrst DAT imaging study was
conducted in 6 adults with ADHD by using 123I-altropane
SPECT, showing that the DAT levels in unmedicated patients
were approximately 70% higher than those in controls [69].
However, following studies with a variety of DAT markers
have shown a much smaller increase even not reaching
statistical signiﬁcance than that found in the ﬁrst study with
123I-altropane [38, 45, 64, 65, 70]. Dresel et al. investigated
DAT binding in 17 treatment na¨ ıve adults with ADHD
compared with 10 age- and gender-matched control subjects
by using 99mTc-TRODAT-1 SPECT. Patients with ADHD
exhibited a signiﬁcantly increased speciﬁc DAT binding in
the striatum (average 17%) compared with normal subjects
(P<0.01) [64]. Furthermore, Krause et al. examined DAT
binding in an expanded sample of 31 adults with ADHD
and 15 control subjects; the earlier ﬁndings of greater DAT
binding in adults with ADHD was replicated [62]. DAT
density has been compared in 9 treatment na¨ ıve children
with ADHD and 6 normal children using 123I-IPT SPECT,
showing that mean DAT binding in the basal ganglia was
signiﬁcantly increased with 40% on the left and 51% on the
right side compared with the controls [70]. By using 11C-
altropane PET, a highly selective radiotracer and technically
superior imaging modality, Spencer et al. found that the
overall DAT binding was increased 28% in adults with
ADHD compared with controls [33]. However, the 123I-β-
CIT SPECT study showed no signiﬁcant diﬀerence in striatal
density between adult patients with ADHD and normal
controls [38]. Furthermore, Hesse et al. found the striatal
DAT binding ratio (speciﬁc to nondisplaceable binding) was
signiﬁcantly reduced in treatment na¨ ıve adults with ADHD
by using 123I-FP-CIT SPECT (ADHD: 5.18 ± 0.98; control:
6.36 ± 1.34) [46]. The cause of divergent ﬁndings might be
the clinical heterogeneity of the ADHD phenotype rather
than diﬀerences in imaging technology, applied tracer type,
or outcome measurement method.
It has been shown that methylphenidate lowers DAT
availability very eﬀectively in normal subjects and in patients
with ADHD. After treatment with methylphenidate (5mg
t.i.d), the speciﬁc DAT binding decreased (average 29%)
signiﬁcantly in all patients (P<0.01), investigated by 99mTc-
TRODAT-1 SPECT [64]. Vles et al. examined DAT binding
in 6 treatment na¨ ıve boys with ADHD (aged 6–10 years),
using 123I-FP-CIT SPECT. Three months after treatment
with methylphenidate, a 28–75% decrease of DAT binding
in the striatum was found [47]. Generally nonresponse to
methylphenidate is known to occur in approximately 30% of
patients with ADHD, which may be caused by lower baseline
DAT availability in these patients. Krause et al. assessed
the relationship between DAT availability and treatment
outcome using 99mTc-TRODAT-1 SPECT. It has shown that
ADHD patients with poor response to methylphenidate had
a low primary DAT availability, whereas most of patients
with high DAT availability exhibited good clinical response
to methylphenidate [66, 67].
Previous studies have conﬁrmed the reduction of DAT
availability by nicotine [60, 61]. Patients with ADHD and
with a history of nicotine abuse displayed lower DAT
availability than nonsmokers with ADHD. DAT seems to
be elevated in nonsmoking ADHD patients suﬀering from
the purely inattentive subtype of ADHD as well as in those
with the combined or purely hyperactive/impulsive subtype
[63, 68].
6. Schizophrenia and the Effects
ofAntipsychotics
Schizophrenia is a chronic mental illness characterized by
disturbances of thoughts, perceptions, volition, and cogni-
tion. Manifestations of the illness are commonly divided into
positive (delusions, hallucinations, thought disorganization,
paranoia), negative (lack of drive and motivation, alogia,
social withdrawal), and cognitive symptoms (poor perfor-
mance on cognitive tasks involving attention and working
memory). Positive symptoms are considered to be a result of
the increased subcorticalrelease of dopamine causing greater
stimulation of D2 receptors. The negative and cognitive
symptoms are thought to arise from reduced D1 receptor
stimulation [28, 90, 116].
Withtheadvanceofbrainimagingtechniques,directevi-
dence suggestive of dysregulation of dopaminergic transmis-
sioninschizophreniahasemerged.Severallinesofstudyhave
documented an increase in the striatal accumulation of 18F-
DOPA or 11C-DOPA in patients with schizophrenia, which
is consistent with increased activity of DOPA decarboxylase,
an enzyme involved in dopamine synthesis [28, 90]. More
recently, Howes et al. assessed striatal dopaminergic function
in patients with prodromal schizophrenia using 18F-DOPA
PET and found elevated striatal 18F-DOPA uptake, which
gradually reached the level in those with schizophrenia. In
addition, increased striatal 18F-DOPA uptake was correlated
with the severity of prodromal psychopathologic and neu-
ropsychological impairment [29].
Since the primary target of many antipsychotic drugs
is antagonism at striatal D2 receptors, Abi-Dargham et al.
compared striatal D2 receptor availability before and during
pharmacologically induced acute dopamine depletion with
123I-IBZM SPECT in 18 untreated patients and 18 controls.
At baselines, no diﬀerence has been found between these 2
groups. However, after depletion of endogenous dopamine,
D2 receptor availability was signiﬁcantly higher in patients
with schizophrenia compared with controls (P<0.01). In
addition, the study suggests elevated synaptic dopamine is
predictive of good treatment response of positive symptoms
to antipsychotic drugs [90].
PET studies with 11C-SCH2390 or 11C-NNC112 in
drug na¨ ıve schizophrenia patients have reported divergent10 Journal of Biomedicine and Biotechnology
ﬁndings in D1 receptor binding and cognitive functioning.
SomestudieshaveshownadecreaseinprefrontalD1 receptor
binding [72], whereas others have shown an increase in D1
receptor binding [71]o rr e p o r t e dn od i ﬀerences between
patients and controls [73]. A few have shown a relationship
between D1 dysfunction and working memory performance
in treatment na¨ ıve patients. The variability in the results was
possibly inﬂuenced by parameters of the particular patient
populations including duration of illness, symptoms and
medications.
Nuclear medicine imaging technique has been widely
used for the drug development in recent years. There are
several approaches such as microdosing, measurement of in
vivo receptor occupancy, and biomarkers [117]. Most imag-
ing studies in the past have concentrated on antipsychotics.
Severallinesofresearchindicatetheeﬃcacyofantipsychotics
to be related to their capacity to antagonize dopamine.
Brain Imaging with PET or SPECT allows determination of
dopamine D2 receptor occupancy rate in the human brain
during treatment with antipsychotics, which are associated
with extrapyramidal symptoms (EPS) of antipsychotic drugs
[118]. Farde et al. found that the classical antipsychotics
occupied 60–85% of striatal dopamine D2 receptor was
necessary for treating positive symptoms of schizophrenia,
as measured by 11C-raclopride PET imaging. However, D2
receptor occupancies above 80% were associated with a
signiﬁcantly higher risk of extrapyramidal symptoms [87,
118, 119].
Several new antipsychotics have been introduced to
market with lower aﬃnity for dopamine D2 receptors, for
which the term “atypical antipsychotics” had been coined.
Atypical antipsychotics display with a low or nonexistent
propensity of extrapyramidal symptoms as compared to
classical neuroleptics [88].
Therapeutic concentrations reported from clinical stud-
ies have been conﬁrmed by D2 receptor imaging for classical
antipsychotics and a number of atypical antipsychotics (i.e.,
amisulpride, clozapine, olanzapine, quetiapine, risperidone,
sertindole,andzotepine).Fromavailablestudies,theatypical
antipsychotics clozapine and quetiapine appear to have the
lowest striatal D2 receptor occupancy rates and the typi-
cal antipsychotic haloperidol has the highest. Risperidone,
sertindole, and zotepine hold an intermediate position.
The incidence of EPS ranged from none with clozapine,
olanzapine, quetiapine, to 80% of patients treated with
haloperidol [89, 91, 92, 120]. The eﬀect of DAT on a
neuroleptic was examined by 123I-FP-CIT SPECT. Mateos
and coworkers found in schizophrenic patients 4 weeks of
treatment with risperidone did not inﬂuence striatal DAT
binding ratios signiﬁcantly [48].
7. Conclusions
With the appropriate radiotracers, neuroimaging enables the
visualization of the presynaptic and postsynaptic sites in
the dopaminergic system. Imaging these markers provides
key insights into the pathophysiology of Parkinson’s disease
and related neurodegenerative diseases and it becomes an
important endpoint in clinical trials of potential disease-
modifying therapy for Parkinson’s disease such as gene
therapy or cell replacement therapy. The availability of
easy-to-apply diagnostic procedures such as metabolic and
DAT imaging is encouraging. Nonetheless, it should also be
emphasized that these results are no replacement for thor-
ough clinical investigation. Future studies are needed in the
development of new radiotracers to target nondopaminergic
brain pathways and the glial reaction to disease.
Neuroimaging studies have provided evidences of how
the human brain changes as an individual becomes
addicted. Although available studies have mostly focused
on dopamine, the interaction of dopamine with other neu-
rotransmitters suchas GABA, glutamate,and serotonin plays
an important role in modulating the magnitude of the
dopamine responses to drugs.
At this time, knowledge from DAT imaging studies in
patients with ADHD is limited by the use of various radio-
tracers and small sample size. In the future, measurements
of DAT with PET or SPECT should be performed in greater
collectives, allowing the assignment to diﬀerent subtypes
of ADHD. Of further interest will be whether the DAT
availability has a prognostic value for the treatment response
of methylphenidate. Furthermore, since methylphenidate
exerts its therapeutic eﬃcacy is through blocking DAT
and NET, the role of norepinephrinergic system in the
pathophysiologyofADHDwillbecomeincreasingimportant
as the recently available of NET radiotracers.
The clinically most important contribution from neu-
roimaging on D2 receptor occupancy in patients with
schizophrenia is probably the identiﬁcation of the optimal
therapeutic window for antipsychotic drugs. Based on this
concept, the striatal D2 receptors binding proﬁles of typical
and atypical antipsychotic agents has been determined.
In the future, the role of neuroimaging may become
more signiﬁcant in guiding therapy. Enhancements in image
resolution and speciﬁc molecular tags will permit accurate
diagnoses of a wide range of diseases, based on both struc-
tural and molecular changes in the brain. For widespread
application, advances in molecular imaging should include
thecharacterizationofnewradiotracers,applicationofmod-
eling techniques, standardization and automation of image-
processing techniques, and appropriate clinical settings in
large multicenter trials. The growing ﬁeld of neuroimaging is
helping nuclear medicine physicians identify pathways into
personalized patient care.
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